Analysis from the DART trial across multiple #rarecancer types: Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609)

Honored to publish our study: "Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women" in Jama Oncology! https://t.co/Rfx7v7DHAD @SWOG @KalinskyKevin @lynnhenrymd @ExactSciences

Awesome 👏🏾 @barbarasegarra 👏🏾 Honored to be included in @barbarasegarra’s plenary session @SABCSSanAntonio and proud to work alongside you! @SWOG @OncoAlert @oncodaily #breastcancer #bcsm #advocates #clinicaltrials #research #oncoalert #SABCS25

Speak up. Spend freely. Tell Congress to create a de minimis tax exemption for Bitcoin that allows us to spend our money on gas, groceries, and everyday costs with no strings attached. Act today.

Are you starting treatment for #ALAmyloidosis? Ask your doctor about #clinicaltrial S2213. It compares using a drug combination called Dara-VCD vs. stem cell transplant. Learn more at https://t.co/0h5ZRC6aze. Or call 1-800-4-CANCER. #raredisease

The S2409 PRISM trial biomarker-tests patients with extensive stage small cell #LungCancer during induction treatment and assigns them to 1 of 3 maintenance therapy cohorts based on #SCLC subtype and SLFN11 status. #LCSM Co-PI: So Yeon Kim, MD @YaleCancer https://t.co/xLcUDLFeRa

S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT. Focal, non-diffuse carcinoma in situ (CIS) is allowed. Systematic biopsies needed at post-NAT TURBT. Co-PI: Daniel A. Hamstra, MD, PhD @BCMCancerCenter https://t.co/h6AYneI4Qt

AI is reshaping energy demand, and we’re ready. Our Chairman & CEO Mike Wirth shares how we’re powering the future.

The @SWOG has joined @WIN_Consortium allying two organizations with deeply aligned missions to accelerate progress against cancer and advance precision oncology and biomarker-driven research. @weldeiry @Dr_R_Kurzrock @SWOGChair

AL #amyloidosis trial S2213 compares autologous transplant to Dara-VCD consolidation. Also compares post-consolidation #PatientReportedOutcomes for physical function and other #HRQoL measures. QoL/PRO Co-PI: @Terri_ParkerMD @YaleCancer https://t.co/j7v1cZOwp7

S2427 (BRIGHT) is a study for people who were treated for muscle invasive #BladderCancer — and the cancer shrunk or can’t be found after treatment. The study asks if a drug plus radiation can help prevent bladder removal. Visit https://t.co/WWqP6qxd2M. Or call 1-800-4-CANCER.

S2409 (the PRISM trial) is a study for people with extensive stage small cell lung cancer (ES-SCLC). The goal is to match different #SCLC subtypes with the best treatment. Visit https://t.co/JK0Y59hyUJ. Or call 1-800-4-CANCER. #LCSM

When we say Amazon shipments are easy now, we mean it. Boxem makes them quicker & easier than ever before Get a free trial to simplifying your Amazon shipments & analytics today:

Our @SWOGChair blog: SWOG at SABCS: A Record of Success The San Antonio Breast Cancer Symposium has been a prime venue for publishing important SWOG research results in breast cancer treatment, symptom management, and prevention. #SABCS25 https://t.co/cVjCaGnT8B

On my way to SABCS. Excited & a little scared, as I carry the huge responsibility of representing the hundreds of advocates who have been working for decades to bring patients’ needs & experiences into research.Plenarysession Thursday 8:30. Thank you @SWOG for all I have learned!

Fred Hutch's @MinFang17 presenting work at #ASH25 showing chromosome genomic array testing (CGAT) improves diagnostic yield in patients with #AML and #MDS and has the potential for better risk stratification - a @theNCI myelomatch and @SWOG report. https://t.co/EjMQIOSQXz

Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation [Jan 10, 2019] @DrJoeUnger et al. @JAMAOnc https://t.co/36kRNinM7n #ClinicalTrials @SWOG #SWOGonc

The @theNCI #MyeloMATCH precision medicine trial for #AML or #MDS has some initial results that are being presented in an oral presentation and 5 posters at the #ASH25 meeting this weekend! Find out more here > https://t.co/3F00YotqjI @SWOG @eaonc @ALLIANCE_org #NCORP

One API. Send messages on all channels.

Enrolling: @SWOG S2213 in newly diagnosed #ALamyloidosis. Daratumumab + VCD induction, then randomization to autologous stem cell transplant or Dara-VCD consolidation. Patients on both arms get dara maintenance. Co-PI: @SurbhiSidanaMD @StanfordMed https://t.co/j7v1cZOwp7

#Clinicaltrial S2213 asks if a drug combination (called Dara-VCD) or stem cell transplant is better for people with AL #amyloidosis. The trial is for people who haven’t started treatment yet. Learn more at https://t.co/0h5ZRC6aze. Or call 1-800-4-CANCER.

Isatuximab for relapsed and/or refractory AL amyloidosis. N=43, hematologic response: 77%, renal response: 50%, cardiac response: 57% @Myeloma_Doc #amyloidosis @SWOG https://t.co/gsF1fUQGkE

S2409 PRISM is testing whether it’s feasible to identify each patient’s small cell #LungCancer subtype and use that information to select the best therapy for that patient. #SCLC Co-PI: Alberto Chiappori, MD @MoffittNews https://t.co/xLcUDLFeRa

Web designers like @reijowrites bring powerful interactions to the web with one platform: Framer

If patients w #MIBC have a clinically sig response to NAT, is cystectomy needed? S2427 BRIGHT trial tests whether pembro + RT can let patients keep their bladder. Systematic biopsies needed at post-NAT TURBT. Co-PI: Abhishek Tripathi, MD @cityofhope https://t.co/h6AYneI4Qt